Douglas T. Dieterich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Douglas T. Dieterich has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Kaushik Agarwal
Department of Medicine, Mount Sinai Medical Center, One Gustave Levy Place, New York, NY 10029-6574, USA
4 shared publications- Nickolas Kontorinis
Division of Liver Diseases, Recanati-Miller Transplantation Institute, New York, NY 10029, USA
3 shared publications - James S. Park
NYU Langone Health, New York, NY, USA
2 shared publications Neeraj Saraf
2 shared publicationsJames Love
Department of Medicine, Mt. Sinai Medical Center, New York, New York
1 shared publication- Jaromir Mikl
SUNY at Albany, School of Public Health, Rensselaer NY, USA
1 shared publication
Latest Publications
- Open Access
- 14 December 2009
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 9 (1) , 203
Hepatic profile analyses of tipranavir in Phase II and III clinical trials
The risk and course of serum transaminase elevations (TEs) and clinical hepatic serious adverse event (SAE) development in ritonavir-boosted tipranavir (TPV/r) 500/200 mg BID recipients, who also received additional combination antiretroviral treatment agents in clinical trials (TPV/r-based cART), was determined.
- 14 December 2009
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 9 (1) , 203
Open AccessHepatic profile analyses of tipranavir in Phase II and III clinical trials
The risk and course of serum transaminase elevations (TEs) and clinical hepatic serious adverse event (SAE) development in ritonavir-boosted tipranavir (TPV/r) 500/200 mg BID recipients, who also received additional combination antiretroviral treatment agents in clinical trials (TPV/r-based cART), was determined.
- 1 February 2006
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 8 (1) , 67-74
HBV plus HCV, HCV plus HIV, HBV plus HIV
Coinfection of hepatitis C virus (HCV), hepatitis B virus (HBV), and HIV is common due to shared modes of transmission. These coinfections accelerate the course of chronic liver disease and facilitate progression to cirrhosis and hepatocellular carcinoma. The viral interactions between these viruses are complex, and their treatment may be challenging for clinicians.
- 1 February 2006
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 8 (1) , 67-74
HBV plus HCV, HCV plus HIV, HBV plus HIV
Coinfection of hepatitis C virus (HCV), hepatitis B virus (HBV), and HIV is common due to shared modes of transmission. These coinfections accelerate the course of chronic liver disease and facilitate progression to cirrhosis and hepatocellular carcinoma. The viral interactions between these viruses are complex, and their treatment may be challenging for clinicians.
- 19 January 2006
- Vol. 8 (1) , 16
Disease management--constructing optimal NRTI-based combinations: past, present, and future.
- 19 January 2006
- Vol. 8 (1) , 16
Disease management--constructing optimal NRTI-based combinations: past, present, and future.
- Open Access
- 19 January 2006
- Published by Wiley in Journal of the International AIDS Society
- Vol. 8 (1) , 16
Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future
- 19 January 2006
- Published by Wiley in Journal of the International AIDS Society
- Vol. 8 (1) , 16
Open AccessDisease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future
- 1 May 2005
- Published by Springer Nature in Current Hepatitis Reports
- Vol. 4 (2) , 68-74
Antiviral therapy in the HCV-coinfected patient with HIV and/or HBV
- 1 May 2005
- Published by Springer Nature in Current Hepatitis Reports
- Vol. 4 (2) , 68-74
Antiviral therapy in the HCV-coinfected patient with HIV and/or HBV
- 1 December 2004
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 7 (6) , 451-458
Alcoholic Hepatitis
Alcoholic hepatitis (AH) is a common disease associated with significant morbidity and mortality. Most often the diagnosis is suggested by a history of heavy alcohol excess in a patient with features of hepatic decompensation. In its purest form, AH is a histologic diagnosis of acute hepatic inflammation in response to alcohol. The primary objective of treatment for AH is to support long-term alcohol abstinence and to achieve adequate nutrition with lifestyle modification; goal setting and education are integral to long-term medical management. Severity at presentation (calculated by way of the Maddrey score) determines outcome. Patients with AH represent a heterogeneous group with regard to severity and pathogenesis, with various therapeutic interventions assessed in patients with severe AH. To date, corticosteroids have been studied most, and despite remaining controversial, warrant a place in the treatment of selected patients. Recent advances in unraveling the aspects of disease pathogenesis in AH have raised the possibility of targeted therapies, such as anti-tumor necrosis factor-α monoclonals and pentoxifylline. Orthotopic liver transplantation is not recommended for patients with severe acute AH, as most have an unclear long-term prognosis in the context of ongoing excess alcohol ingestion at presentation.
- 1 December 2004
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 7 (6) , 451-458
Alcoholic Hepatitis
Alcoholic hepatitis (AH) is a common disease associated with significant morbidity and mortality. Most often the diagnosis is suggested by a history of heavy alcohol excess in a patient with features of hepatic decompensation. In its purest form, AH is a histologic diagnosis of acute hepatic inflammation in response to alcohol. The primary objective of treatment for AH is to support long-term alcohol abstinence and to achieve adequate nutrition with lifestyle modification; goal setting and education are integral to long-term medical management. Severity at presentation (calculated by way of the Maddrey score) determines outcome. Patients with AH represent a heterogeneous group with regard to severity and pathogenesis, with various therapeutic interventions assessed in patients with severe AH. To date, corticosteroids have been studied most, and despite remaining controversial, warrant a place in the treatment of selected patients. Recent advances in unraveling the aspects of disease pathogenesis in AH have raised the possibility of targeted therapies, such as anti-tumor necrosis factor-α monoclonals and pentoxifylline. Orthotopic liver transplantation is not recommended for patients with severe acute AH, as most have an unclear long-term prognosis in the context of ongoing excess alcohol ingestion at presentation.
- 1 October 2004
- p. S4
HIV/HCV coinfection in clinical practice.
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) frequently co-exist due to shared routes of transmission. In the past, the impact of HCV on overall morbidity and mortality of coinfected patients was minimal due to the poor prognosis of HIV. However, since the introduction of highly active antiretroviral therapy (HAART), HCV has become a significant pathogen in this population. HIV clearly exacerbates HCV infection and accelerates progression to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. There is debate over whether HCV influences the natural history of HIV. Given the high prevalence of coinfection and the accelerated liver damage, HCV treatment has become a priority in these patients. There are new data on pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy for HCV in coinfected patients. The therapy is well tolerated and safe, although it appears to be slightly less effective than in monoinfected patients. The risk of HAART-related hepatotoxicity is greater in coinfected patients and therefore requires special consideration and close monitoring.
- 1 October 2004
- p. S4
HIV/HCV coinfection in clinical practice.
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) frequently co-exist due to shared routes of transmission. In the past, the impact of HCV on overall morbidity and mortality of coinfected patients was minimal due to the poor prognosis of HIV. However, since the introduction of highly active antiretroviral therapy (HAART), HCV has become a significant pathogen in this population. HIV clearly exacerbates HCV infection and accelerates progression to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. There is debate over whether HCV influences the natural history of HIV. Given the high prevalence of coinfection and the accelerated liver damage, HCV treatment has become a priority in these patients. There are new data on pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy for HCV in coinfected patients. The therapy is well tolerated and safe, although it appears to be slightly less effective than in monoinfected patients. The risk of HAART-related hepatotoxicity is greater in coinfected patients and therefore requires special consideration and close monitoring.
- Open Access
- 1 March 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (Supplement) , S80-S89
Drug-Induced Liver Injury Associated with the Use of Nonnucleoside Reverse-Transcriptase Inhibitors
Human immunodeficiency virus (HIV)-infected patients frequently present with elevated levels of serum transaminases (alanine aminotransferase [ALT] a
- 1 March 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (Supplement) , S80-S89
Open AccessDrug-Induced Liver Injury Associated with the Use of Nonnucleoside Reverse-Transcriptase Inhibitors
Human immunodeficiency virus (HIV)-infected patients frequently present with elevated levels of serum transaminases (alanine aminotransferase [ALT] a
- Open Access
- 1 March 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (Supplement) , S43
Hepatic Safety
The present supplement summarizes presentations made at a special conference sponsored by Boehringer Ingelheim International entitled “Hepatic Safety and HAART.” It took place in Santa Barbara, California, on 7–9 June 2002.
- 1 March 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (Supplement) , S43
Open AccessHepatic Safety
The present supplement summarizes presentations made at a special conference sponsored by Boehringer Ingelheim International entitled “Hepatic Safety and HAART.” It took place in Santa Barbara, California, on 7–9 June 2002.